These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 29335867)

  • 61. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma.
    Zannoni GF; Improta G; Chiarello G; Pettinato A; Petrillo M; Scollo P; Scambia G; Fraggetta F
    Virchows Arch; 2014 Aug; 465(2):193-8. PubMed ID: 24889043
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.
    Foltran L; De Maglio G; Pella N; Ermacora P; Aprile G; Masiero E; Giovannoni M; Iaiza E; Cardellino GG; Lutrino SE; Mazzer M; Giangreco M; Pisa FE; Pizzolitto S; Fasola G
    Future Oncol; 2015; 11(4):629-40. PubMed ID: 25686118
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Deep Learning Features Improve the Performance of a Radiomics Signature for Predicting KRAS Status in Patients with Colorectal Cancer.
    Wu X; Li Y; Chen X; Huang Y; He L; Zhao K; Huang X; Zhang W; Huang Y; Li Y; Dong M; Huang J; Xia T; Liang C; Liu Z
    Acad Radiol; 2020 Nov; 27(11):e254-e262. PubMed ID: 31982342
    [TBL] [Abstract][Full Text] [Related]  

  • 64. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma.
    Cicenas J; Tamosaitis L; Kvederaviciute K; Tarvydas R; Staniute G; Kalyan K; Meskinyte-Kausiliene E; Stankevicius V; Valius M
    Med Oncol; 2017 Feb; 34(2):26. PubMed ID: 28074351
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.
    Segelov E; Waring P; Desai J; Wilson K; Gebski V; Thavaneswaran S; Elez E; Underhill C; Pavlakis N; Chantrill L; Nott L; Jefford M; Khasraw M; Day F; Wasan H; Ciardiello F; Karapetis C; Joubert W; van Hazel G; Haydon A; Price T; Tejpar S; Tebbutt N; Shapiro J
    BMC Cancer; 2016 May; 16():339. PubMed ID: 27246726
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of KRAS, NRAS and BRAF mutations detection in plasma using an automated system for patients with metastatic colorectal cancer.
    Franczak C; Witz A; Geoffroy K; Demange J; Rouyer M; Husson M; Massard V; Gavoille C; Lambert A; Gilson P; Gambier N; Scala-Bertola J; Merlin JL; Harlé A
    PLoS One; 2020; 15(1):e0227294. PubMed ID: 31940389
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Somatic Mutations in the BRAF, KRAS, NRAS, EIF1AX, and TERT Genes: Diagnostic Value in Thyroid Neoplasms.
    Kachko VA; Vanushko VE; Platonova NM; Abrosimov AY; Mel'nichenko GA
    Bull Exp Biol Med; 2020 Sep; 169(5):669-672. PubMed ID: 32990852
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Significance of RAS mutations in pulmonary metastases of patients with colorectal cancer.
    Igarashi T; Shimizu K; Usui K; Yokobori T; Ohtaki Y; Nakazawa S; Obayashi K; Yajima T; Nobusawa S; Ohkawa T; Katoh R; Motegi Y; Ogawa H; Harimoto N; Ichihara T; Mitani Y; Yokoo H; Mogi A; Shirabe K
    Int J Clin Oncol; 2020 Apr; 25(4):641-650. PubMed ID: 31773354
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A multicenter study: predicting KRAS mutation and prognosis in colorectal cancer through a CT-based radiomics nomogram.
    Li M; Yuan Y; Zhou H; Feng F; Xu G
    Abdom Radiol (NY); 2024 Jun; 49(6):1816-1828. PubMed ID: 38393357
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance.
    Módos O; Reis H; Niedworok C; Rübben H; Szendröi A; Szász MA; Tímár J; Baghy K; Kovalszky I; Golabek T; Chlosta P; Okon K; Peyronnet B; Mathieu R; Shariat SF; Hollósi P; Nyirády P; Szarvas T
    Oncotarget; 2016 Jun; 7(26):39293-39301. PubMed ID: 27283768
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series.
    Mahdi Y; Khmou M; Souadka A; Agouri HE; Ech-Charif S; Mounjid C; Khannoussi BE
    BMC Gastroenterol; 2023 Jun; 23(1):193. PubMed ID: 37277698
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1
    Mesti T; Rebersek M; Ocvirk J
    Radiol Oncol; 2023 Mar; 57(1):103-110. PubMed ID: 36942906
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Computed Tomography-Based Radiomic Features Could Potentially Predict Microsatellite Instability Status in Stage II Colorectal Cancer: A Preliminary Study.
    Fan S; Li X; Cui X; Zheng L; Ren X; Ma W; Ye Z
    Acad Radiol; 2019 Dec; 26(12):1633-1640. PubMed ID: 30929999
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CT Texture Analysis: A Potential Biomarker for Evaluating KRAS Mutational Status in Colorectal Cancer.
    Cao J; Wang GR; Wang ZW; Jin ZY
    Chin Med Sci J; 2020 Dec; 35(4):306-314. PubMed ID: 33413746
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer.
    Guo TA; Wu YC; Tan C; Jin YT; Sheng WQ; Cai SJ; Liu FQ; Xu Y
    Int J Cancer; 2019 Sep; 145(6):1625-1634. PubMed ID: 31162857
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Microsatellite Instability in Greek Colorectal Carcinoma Patients: Clinicopathological and Molecular Correlations.
    Katafygiotis P; Sakellariou S; Chatziandreou I; Giannopoulou I; Thymara I; Saetta AA; Korkolopoulou P
    Anticancer Res; 2019 Nov; 39(11):6379-6387. PubMed ID: 31704871
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical Significance of Somatic Mutations in RAS/RAF/MAPK Signaling Pathway in Moroccan and North African Colorectal Cancer Patients.
    Benmokhtar S; Laraqui A; El Boukhrissi F; Hilali F; Bajjou T; Jafari M; El Zaitouni S; Baba W; El Mchichi B; Elannaz H; Lahlou IA; Chahdi H; Oukabli M; Mahfoud T; Tanz R; Ichou M; Ennibi K; Dakka N; Sekhsokh Y
    Asian Pac J Cancer Prev; 2022 Nov; 23(11):3725-3733. PubMed ID: 36444585
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing.
    Sakai K; Tsurutani J; Yamanaka T; Yoneshige A; Ito A; Togashi Y; De Velasco MA; Terashima M; Fujita Y; Tomida S; Tamura T; Nakagawa K; Nishio K
    PLoS One; 2015; 10(5):e0121891. PubMed ID: 25954997
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer.
    Prieto-Potin I; Montagut C; Bellosillo B; Evans M; Smith M; Melchior L; Reiltin W; Bennett M; Pennati V; Castiglione F; Bürrig KF; Cooper U; Dockhorn-Dworniczak B; Rossenbach C; Luna-Aguirre CM; Barrera-Saldaña HA; Machado JC; Costa JL; Yacobi R; Tabibian-Keissar H; Buglioni S; Ronchetti L; Douglas-Berger L; Dubbink HJ; Alorini M; Sabourin JC; Rojo F
    J Mol Diagn; 2018 Sep; 20(5):664-676. PubMed ID: 29959022
    [TBL] [Abstract][Full Text] [Related]  

  • 80. RAS status in Korean patients with stage III and IV colorectal cancer.
    Lee WS; Lee JN; Baek JH; Park YH
    Clin Transl Oncol; 2015 Sep; 17(9):751-6. PubMed ID: 25997687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.